William L Walker1, Susan L Hills2, Elaine R Miller3, Marc Fischer4, Ingrid B Rabe4. 1. Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, United States; Epidemic Intelligence Service, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, United States. 2. Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, United States. Electronic address: shills@cdc.gov. 3. Immunization Safety Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333, United States. 4. Arboviral Diseases Branch, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, United States.
Abstract
BACKGROUND: In March 2009, the U.S. Food and Drug Administration licensed an inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [IXIARO®]) for use in persons aged ≥17 years. In 2013, licensure was extended to include children aged ≥2 months. A previous analysis reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from May 2009 through April 2012. METHODS: We reviewed adverse events reported to VAERS following JE-VC administered from May 1, 2012 through April 30, 2016. Adverse event reporting rates were calculated using 802,229 doses distributed. RESULTS: During the 4-year period, 119 adverse event reports were received for a reporting rate of 14.8 per 100,000 doses distributed. Nine (8%) adverse events were classified as serious for a reporting rate of 1.1 per 100,000 distributed. The most commonly reported event was hypersensitivity (n = 24; 20%) for a rate of 3.0 per 100,000 doses distributed; 1 anaphylaxis event was reported. Ten (8%) neurologic events were reported for a rate of 1.2 per 100,000 doses distributed; 2 events were classified as seizures. Sixty-three (53%) adverse events occurred after a first dose of JE-VC. Eighty (67%) adverse events occurred after administration of JE-VC with other vaccines. Eleven (9%) adverse events were reported in children; 1 was considered serious. CONCLUSIONS: These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events. Published by Elsevier Ltd.
BACKGROUND: In March 2009, the U.S. Food and Drug Administration licensed an inactivated Vero cell culture-derived Japanese encephalitis vaccine (JE-VC [IXIARO®]) for use in persons aged ≥17 years. In 2013, licensure was extended to include children aged ≥2 months. A previous analysis reviewed adverse events reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from May 2009 through April 2012. METHODS: We reviewed adverse events reported to VAERS following JE-VC administered from May 1, 2012 through April 30, 2016. Adverse event reporting rates were calculated using 802,229 doses distributed. RESULTS: During the 4-year period, 119 adverse event reports were received for a reporting rate of 14.8 per 100,000 doses distributed. Nine (8%) adverse events were classified as serious for a reporting rate of 1.1 per 100,000 distributed. The most commonly reported event was hypersensitivity (n = 24; 20%) for a rate of 3.0 per 100,000 doses distributed; 1 anaphylaxis event was reported. Ten (8%) neurologic events were reported for a rate of 1.2 per 100,000 doses distributed; 2 events were classified as seizures. Sixty-three (53%) adverse events occurred after a first dose of JE-VC. Eighty (67%) adverse events occurred after administration of JE-VC with other vaccines. Eleven (9%) adverse events were reported in children; 1 was considered serious. CONCLUSIONS: These data continue to support the generally favorable safety profile of JE-VC. Reporting rates of adverse events were similar to those of the previous analysis. Although reporting rates of adverse events in children could not be calculated, there were low numbers of reported events in this age group. Post-licensure adverse event surveillance for this relatively new vaccine continues to be important to monitor adverse event reporting rates and identify possible rare serious events. Published by Elsevier Ltd.
Entities:
Keywords:
Adverse event; Children; Japanese encephalitis; VAERS; Vaccine
Authors: Jan Bonhoeffer; John Menkes; Michael S Gold; Glacus de Souza-Brito; Margaret C Fisher; Neal Halsey; Patricia Vermeer Journal: Vaccine Date: 2004-01-26 Impact factor: 3.641
Authors: James J Sejvar; Katrin S Kohl; Jane Gidudu; Anthony Amato; Nandini Bakshi; Roger Baxter; Dale R Burwen; David R Cornblath; Jan Cleerbout; Kathryn M Edwards; Ulrich Heininger; Richard Hughes; Najwa Khuri-Bulos; Rudolf Korinthenberg; Barbara J Law; Ursula Munro; Helena C Maltezou; Patricia Nell; James Oleske; Robert Sparks; Priscilla Velentgas; Patricia Vermeer; Max Wiznitzer Journal: Vaccine Date: 2010-06-18 Impact factor: 3.641
Authors: James J Sejvar; Katrin S Kohl; Roman Bilynsky; Dean Blumberg; Therese Cvetkovich; Jochem Galama; Jane Gidudu; Lakshmi Katikaneni; Najwa Khuri-Bulos; James Oleske; Terhi Tapiainen; Max Wiznitzer Journal: Vaccine Date: 2007-05-11 Impact factor: 3.641
Authors: Katrin Dubischar-Kastner; Astrid Kaltenboeck; Anton Klingler; Bernd Jilma; Elisabeth Schuller Journal: Vaccine Date: 2010-07-29 Impact factor: 3.641
Authors: Jakob P Cramer; Katrin Dubischar; Susanne Eder; Gerd D Burchard; Tomas Jelinek; Bernd Jilma; Herwig Kollaritsch; Emil Reisinger; Kerstin Westritschnig Journal: Vaccine Date: 2016-07-25 Impact factor: 3.641